<DOC>
	<DOC>NCT03055494</DOC>
	<brief_summary>This study will provide a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.</brief_summary>
	<brief_title>Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Written informed consent must be obtained before any assessment is performed Clinical diagnosis of chronic plaquetype psoriasis at least 6 months prior to randomization Moderate to severe plaque psoriasis as defined at baseline by: ≥10% Body Surface Area (BSA) involvement and PASI total score of ≥12 and IGA mod 2011 score of ≥3 (based on a scale of 04) Forms of diagnosed psoriasis other than chronic plaque psoriasis Medicationinduced or medication exacerbated psoriasis Previous exposure to secukinumab or any other biologic drug directly targeting IL17A or IL17RA receptors Ongoing use of prohibited treatments Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>